中国药业2023，Vol.32Issue(24)：138-141,4.DOI:10.3969/j.issn.1006-4931.2023.24.032
基于Markov模型的纳武利尤单抗治疗晚期/复发性食管鳞状细胞癌药物经济学研究
Pharmacoeconomic Study of Nivolumab in the Treatment of Advanced/Recurrent Esophageal Squamous Cell Carcinoma Based on Markov Model
摘要
Abstract
Objective To evaluate the economy of nivolumab in the treatment of advanced/recurrent esophageal squamous cell carcinoma(ESCC)from the perspective of healthcare system in China.Methods A Markov model based on the data from ATTRACTION-3 trial was constructed to estimate the cost and effectiveness of nivolumab(nivolumab group)and conventional chemical drugs such as docetaxel or paclitaxel(conventional chemotherapy group)for patients with refractory or intolerable,advanced(unresectable)or recurrent ESCC after prior fluoropyrimidine-and platinum-based chemotherapy,and the incremental cost-effectiveness ratio(ICER)was calculated.The robustness of the model was explored by the one-way sensitivity analysis and probabilistic sensitivity analysis.Results Compared with the conventional chemotherapy group,the nivolumab group increased costs by CNY 211 141.52,while gaining additional 0.34 quality-adjusted life years(QALYs),resulting in an ICER of CNY 621 004.47 per QALY,which was above the willingness-to-pay(WTP)threshold(CNY 242 928).It was speculated that when the WTP was CNY 1 419 120,the cost-effectiveness probability of nivolumab was 0.503.Conclusion From the perspective of healthcare system in China,nivolumab has no cost-effectiveness advantage for patients with refractory or intolerable,advanced(unresectable)or recurrent ESCC after prior fluoropyrimidine-and platinum-based chemotherapy.关键词
纳武利尤单抗/食管鳞状细胞癌/晚期/复发性/Markov模型/成本-效用/药物经济学Key words
nivolumab/esophageal squamous cell carcinoma/advanced/recurrent/Markov model/cost-effectiveness/pharmacoeconomics分类
医药卫生引用本文复制引用
黎风,何梅,李茂玉..基于Markov模型的纳武利尤单抗治疗晚期/复发性食管鳞状细胞癌药物经济学研究[J].中国药业,2023,32(24):138-141,4.基金项目
2022白求恩·求索-药学科研能力建设项目. （）
